<DOC>
	<DOC>NCT01240382</DOC>
	<brief_summary>To investigate that the efficacy of 3% DE-089 ophthalmic solution (one drop at a time, 6 times daily, 4 weeks topical administration), in comparison to 0.1% sodium hyaluronate ophthalmic solution (0.1% HA) (one drop at a time, 6 times daily, 4 weeks topical administration), is at least non-inferior in the change in fluorescein staining score, and is superior in the change in Rose bengal score, in a multicenter, double-masked, parallel-group comparison study. Safety profile will likewise be compared.</brief_summary>
	<brief_title>Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Those who show: Keratoconjunctival disorder confirmed with vital dye staining Abnormal Schirmer score results Eye disease that needs therapy other than that for dry eye Those who need to wear contact lenses during the clinical study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>